Drug intelligence / Profile preview

HGP1607

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules

Overview

HGP1607 is a small molecule drug developed by Hanmi Pharmaceutical. It has been studied in early-phase clinical trials, specifically in a randomized, open-label, crossover Phase 1 study to investigate pharmacokinetic drug interactions and safety between HGP1607 and another compound (HGP1501) in healthy male volunteers. The primary therapeutic area appears to be endocrinology and metabolic diseases, with osteoporosis listed as an inactive indication. The precise mechanism of action and molecular target for HGP1607 have not been disclosed publicly[1][3][4].

Beyond the preview

Go deeper on HGP1607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP1607.

Explore the full profile